Bicycle Therapeutics (ADR) (BCYC)
Develops Bicycle Drug Conjugates and radioconjugates for precision oncology.
Something off on this page? Send us feedback.
Develops precision oncology medicines from its synthetic bicyclic-peptide Bicycle platform, including Bicycle Drug Conjugates and Bicycle Radioconjugates. The clinical-stage pipeline centers on nuzefatide pevedotin and next-generation conjugate programs.
Built around a proprietary platform of chemically synthesized, constrained short peptides with two loops, the company develops precision oncology medicines. Its main modalities are Bicycle Drug Conjugates and Bicycle Radioconjugates; nuzefatide pevedotin, formerly BT5528, is an EphA2-targeting Bicycle Drug Conjugate. Discovery research is concentrated in Cambridge, while the organization operates across Cambridge in the United Kingdom and the Boston area.
Execution depends on advancing a selective clinical pipeline, with current emphasis on nuzefatide pevedotin and next-generation Bicycle conjugate programs. Development also depends on clinical-study outcomes and timing, regulatory approvals, intellectual-property protection, strategic partners, financing, and key personnel.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | Jefferies | Target | $12 | |||
| Apr 8, 2026 | Morgan Stanley | Reiterate | Equal Weight | $13 | $12 | |
| Mar 17, 2026 | Truist Financial | Target | $10 | $8 | ||
| Mar 17, 2026 | Morgan Stanley | Target | $17 | $13 | ||
| Nov 24, 2025 | Truist Financial | Target | $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $510.1M · Total debt $13.7M · Total assets $606.6M · Shareholders' equity $510.3M
- Revenue
- $629.0K
- Operating income
- −$54.6M
- Net income
- −$50.3M
No dividends on record.
| Institutions103 holders · as of Mar 31, 2026 | 107.04% | 74.92M ADS | |
| Insiders21 holders · as of Jul 7, 2026 | 4.50% | 3.15M ADS | |
| Adds to | 111.54% |
69.99M ADS as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 111.54%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Baker Bros. Advisors LPInstitution | 31.10% | 10.89M ADS · 10.89M ADS | 13Fas of Mar 31, 2026 |
FCPM Iii Services B.V.Institution | 9.91% | 3.47M ADS · 3.47M ADS | 13Fas of Mar 31, 2026 |
Armistice Capital, LLCInstitution | 9.71% | 3.40M ADS · 3.40M ADS | 13Fas of Mar 31, 2026 |
Long Focus Capital Management, LLCInstitution | 9.46% | 3.31M ADS · 3.31M ADS | 13Fas of Mar 31, 2026 |
Acadian Asset Management LLCInstitution | 5.62% | 1.97M ADS · 1.97M ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 6, 2026 | Travis Alvin Thompson | officer: Chief Financial Officer | −104 | $4.31 |
| Jul 2, 2026 | Travis Alvin Thompson | officer: Chief Financial Officer | −819 | $4.27 |
| Jul 6, 2026 | Michael Charles Ferguson Hannay | officer: CHIEF PROD & SUPPLY CHAIN OFF | −255 | $4.31 |
| Jul 2, 2026 | Michael Charles Ferguson Hannay | officer: CHIEF PROD & SUPPLY CHAIN OFF | −1,506 | $4.27 |
| Jul 6, 2026 | Kevin Lee | director, officer: CHIEF EXECUTIVE OFFICER | −1,737 | $4.31 |
- Pfizer
Targeted oncology conjugates, including Nectin-4 ADCs
- AstraZeneca (ADR)
Targeted ADC and radioconjugate platforms in oncology
- Novartis (ADR)
Commercial radioligand therapies and an expanding RLT portfolio
- Telix Pharmaceuticals
Commercial theranostic radiopharmaceuticals in oncology
- Perspective Therapeutics
Lead-212 peptide-targeted alpha therapies and imaging
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bicycle Therapeutics (ADR) | $4.30 | +4.88% | $298.4M | — | — | 4.9 | −78.5% |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Telix Pharmaceuticals | $11.99 | +4.72% | $3.88B | 114.7 | — | 4.2 | +22.8% |
| Perspective Therapeutics | $3.11 | +0.32% | $353.5M | — | — | 966.0 | −72.1% |
| Median | 31.4 | 15.2 | 4.2 | +2.6% |